MERGER DENIALS BY CIBA-GEIGY
Alex Krauer, managing director of the Swiss chemical and pharmaceutical concern, Ciba-Geigy, has denied that his company could be about to merge with the other Swiss company Roche Holding. Market speculation has fuelled the rumors recently, but Mr Krauer has said that there is no truth in them.
He added that the company's strategy is to grow from within, and that there are no merger plans whatsoever. However, Ciba-Geigy will continue to work with other companies and universities, particularly in the field of biotechnology. Ciba-Geigy already has a number of alliances with start-up biotechnology companies in the USA. Analysts say that the company's strategy will result in it establishing more projects outside of Switzerland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze